The Trump Administration: Seven More Things To Watch Out For

12 Jan 2017

• By Emily Hayes

Beyond pricing, industry experts weigh in on how the next administration has shifted expectations across a range of areas – including tax reform, FDA standards and the Cancer Moonshot Initiative.

Nobody has a crystal ball to show what life will be like in the biopharma world under the incoming Trump administration, but industry experts were willing to share some personal predictions during panels at the Biotech Showcase meeting in San Francisco, held in parallel with the J.P. Morgan Healthcare conference.

The panels took place on Jan. 10, the day before Donald Trump’s market roiling press conference where he advocated bidding...